Search

Troxacitabine

Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

Irofulven

Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. … compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S

Tosufloxacin

CCX915

The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis. … CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

PSN357

PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

LX6171

LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

Apolizumab

Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

Beclamide

Beclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity.

Bimoclomol

Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

CMLVAX100

It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.